THCP has acquired a fairly wild reputation since scientists identified it in cannabis in 2019. Search online and you’ll find it described as a supercharged version of THC, sometimes accompanied by claims that it is 30 or even 33 times stronger.
That’s not quite what the science says.
THCP, short for tetrahydrocannabiphorol, is a naturally occurring cannabinoid with a chemical structure similar to delta-9 THC. Early laboratory research found that it binds very strongly to cannabinoid receptors, particularly CB1 receptors. That finding is genuinely interesting, but it does not mean researchers have demonstrated that THCP makes humans 33 times more potent than ordinary THC.
In fact, human research on THCP remains remarkably thin.
So what do we actually know about THCP, its effects and the claims surrounding its potency?
What is THCP?
THCP is a phytocannabinoid that occurs naturally in Cannabis sativa, although it appears to be present in relatively small quantities compared with better-known cannabinoids such as THC and CBD.
Italian researchers first reported isolating and characterising delta-9-THCP in a scientific paper published at the end of 2019.
Structurally, THCP looks a lot like delta-9 THC. One important difference is its alkyl side chain.
Delta-9 THC has a five-carbon side chain, while THCP has a seven-carbon side chain. That seemingly small difference appears to significantly affect how strongly the molecule interacts with cannabinoid receptors.
The researchers also identified CBDP, or cannabidiphorol, which is the corresponding seven-carbon relative of CBD.
THCP therefore isn’t simply a marketing name invented for a new vape or edible. It is a genuine cannabinoid that has been identified in the cannabis plant.
The difficult part is separating what researchers have actually established from what has happened since THCP entered the commercial cannabinoid market.
Is THCP really 33 times stronger than THC?
This is probably the biggest misunderstanding surrounding THCP.
The original 2019 study found that THCP had a binding affinity of 1.2 nM at the human CB1 receptor, compared with 40 nM for delta-9 THC in the assay the researchers referenced.
They described THCP as having approximately 33 times the binding affinity of delta-9 THC at CB1 receptors.
That is where the famous number comes from.
But receptor binding affinity and the strength of a human high are not the same measurement.
A molecule binding more strongly to a receptor does not allow us to say that someone will become 33 times more intoxicated from an equivalent amount. Human pharmacology depends on absorption, metabolism, dose, receptor activity, tolerance and numerous other factors.
So describing THCP as “33 times stronger than THC” is an oversimplification.
A more accurate statement is that THCP demonstrated much higher CB1 receptor binding affinity than delta-9 THC in laboratory testing.
How does THCP work?
Like delta-9 THC, THCP interacts with the body’s endocannabinoid system.
Two of the best-known components of this system are the CB1 and CB2 cannabinoid receptors.
CB1 receptors are widely expressed in the central nervous system and are closely involved in the intoxicating effects associated with THC. CB2 receptors are found predominantly in immune and peripheral tissues, although cannabinoid receptor biology is considerably more complicated than that simple distinction suggests.
The original THCP study found high binding affinity at both receptors, with particularly strong affinity at CB1.
Researchers then tested THCP in mice using the cannabinoid tetrad, a group of behavioural and physiological tests commonly used in cannabinoid research.
THCP produced THC-like cannabinoid activity in the animals, including reduced movement, catalepsy and reduced body temperature.
Those experiments demonstrated biological activity consistent with a potent cannabinoid.
They did not establish a safe human dose or tell us precisely what THCP feels like in people.
What are the effects of THCP?
This is where the evidence becomes much less satisfying.
Commercial websites often provide confident lists of THCP effects, including euphoria, relaxation, altered perception, appetite changes and sedation.
Some of those descriptions are plausible because THCP interacts with CB1 receptors and has demonstrated THC-like activity in animal experiments.
But controlled human studies establishing a typical THCP effect profile are lacking.
That means we should be careful not to present anecdotal reports as established scientific effects.
People consuming commercial THCP products may report experiences resembling a strong THC high, but those reports are affected by dose, tolerance, other cannabinoids in the product and whether the label accurately reflects what is actually inside it.
If you’re unfamiliar with the better-established cannabinoid, our article on THC and how it behaves in the body explains why even ordinary delta-9 THC can vary considerably between occasional and frequent users.
Can THCP cause a stronger high?
It is reasonable to expect THCP to have psychoactive potential given its activity at CB1 receptors.
What we cannot currently do is provide a scientifically validated conversion such as “1 mg of THCP equals X mg of THC”.
The necessary human dose-response research simply isn’t there.
This matters because commercial cannabinoid products can create a false impression of precision. A package might list an exact number of milligrams, but the scientific evidence needed to interpret that number remains limited.
Someone experienced with conventional cannabis should not assume that their normal THC tolerance allows them to accurately predict their response to THCP.
What do we know about THCP side effects?
We do not yet have enough controlled human evidence to produce a reliable THCP-specific side-effect profile.
Given its cannabinoid receptor activity, researchers and clinicians have reason to consider adverse effects associated with potent psychoactive cannabinoids, but those should not simply be presented as proven THCP outcomes without supporting evidence.
One notable piece of human evidence appeared in 2025.
A published case report described a regular THC user who developed prolonged psychotic symptoms after consuming a product reported to contain 8 mg of delta-9-THCP. The symptoms reportedly continued for around 48 hours and the patient required hospital treatment.
This is important enough to take seriously, but it is still only one case.
A case report cannot establish how frequently such reactions occur, determine a universally dangerous dose or prove that every commercial THCP product presents the same risk.
It does reinforce the broader point that experience with ordinary THC should not be treated as proof that someone will respond predictably to a newer cannabinoid.
How long do THCP effects last?
There isn’t currently a reliable evidence-based answer.
You may encounter websites claiming THCP lasts for a specific number of hours, sometimes considerably longer than THC. Most of those precise figures aren’t supported by robust, controlled human trials.
The 2025 case report described symptoms lasting about 48 hours after consumption, but it was an adverse clinical case rather than a study of normal THCP duration.
It would therefore be misleading to use that case as the expected duration for everyone.
How long any psychoactive cannabinoid affects someone can depend on dose, route of administration, metabolism, tolerance and other substances consumed at the same time.
With THCP, the additional problem is simply that we do not yet have enough human pharmacokinetic data.
What happens if you take too much THCP?
No scientifically established threshold defines “too much” THCP for every person.
That uncertainty is itself a reason to be cautious.
With conventional high-THC cannabis, excessive intoxication can involve anxiety, panic, confusion, paranoia, nausea, vomiting and changes in heart rate. THCP’s strong CB1 activity makes adverse psychoactive reactions a legitimate concern, but THCP-specific incidence data are not available.
If someone has consumed a cannabinoid and is simply uncomfortable, time and a calm, safe environment are often important while the effects subside. Our guide on managing the effects of too much THC separates sensible supportive measures from internet myths about instantly becoming sober.
Serious symptoms are different. Loss of consciousness, seizures, severe chest pain, difficulty breathing, extreme confusion or behaviour creating an immediate risk of harm warrant urgent medical attention.
THCP versus THC
THCP and delta-9 THC are structurally related, but treating them as interchangeable would be a mistake.
| Characteristic | Delta-9 THC | THCP |
|---|---|---|
| Occurs naturally in cannabis | Yes | Yes, apparently in much smaller quantities |
| Alkyl side chain | Five carbon atoms | Seven carbon atoms |
| CB1 receptor activity | Well established | Very high binding affinity in laboratory research |
| Human research | Extensive compared with THCP | Very limited |
| Reliable human dose-response data | Substantially more evidence available | Not well established |
| Long-term safety evidence | Large research literature, although questions remain | Insufficient |
The key difference for consumers is not simply potency. It is how much less we know about THCP.
THCP versus CBD
THCP should not be confused with CBD.
CBD, or cannabidiol, does not produce the characteristic intoxication associated with delta-9 THC. THCP has a completely different receptor profile and has demonstrated strong cannabinoid-like activity.
The names can become especially confusing because researchers who identified THCP also identified CBDP, the seven-carbon homologue of CBD.
CBDP itself remains poorly understood. A 2024 laboratory study examining CBDP receptor activity found that its biological activity was not simply an amplified version of CBD, illustrating why longer side chains should not automatically be translated into claims of greater potency across every cannabinoid.
If you’re interested in the wider chemistry of cannabis, our article on CBD, terpenes and the entourage effect looks at another area where cannabis marketing has often moved faster than the evidence.
Is THCP natural or synthetic?
Natural THCP exists. That was the point of the original 2019 discovery.
However, naturally occurring THCP appears in cannabis at low concentrations.
The THCP found in commercial products therefore deserves a separate question: where did the material actually come from?
THCP can be isolated or produced for commercial formulations, and products sold online may contain combinations of cannabinoids rather than naturally extracted THCP in the proportions found in cannabis flower.
This does not automatically mean a product is unsafe, but it does mean the phrase “naturally occurring cannabinoid” can be misleading when used as a blanket description of a manufactured product.
Something can exist naturally and still be produced, concentrated or formulated industrially.
Do commercial THCP products contain what they claim?
This is difficult to answer without independent laboratory testing.
The wider market for emerging cannabinoids has developed much faster than the scientific literature surrounding many of them.
Labels may list THCP alongside delta-8 THC, HHC, CBD or other cannabinoids. Concentrations and formulations can differ dramatically between manufacturers.
A certificate of analysis from an independent laboratory can provide more useful information than branding alone, although consumers also need to confirm the certificate matches the batch being sold.
This issue is particularly relevant with highly concentrated or novel cannabinoid products because a small labelling error may matter more when the compound has substantial psychoactive activity.
What do we know about THCP metabolism?
Research is only beginning to catch up.
A 2026 study published in the Journal of Analytical Toxicology investigated THCP metabolism alongside related THC homologues THCB and THCH using human liver microsomes.
The researchers identified hydroxylated and carboxylated metabolites broadly similar to metabolic pathways seen with delta-9 THC.
The study was primarily relevant to forensic toxicology rather than determining how long a THCP high lasts. It may eventually help laboratories identify THCP exposure more reliably.
It also illustrates how young this field is. Researchers are still establishing basic information about how THCP is metabolised and how laboratories should identify it.
Will THCP show up on a drug test?
There isn’t enough evidence to promise whether every standard cannabis drug test will or will not detect THCP use.
Drug tests differ in what they measure. Some screening methods look for THC metabolites, while specialist laboratory techniques can distinguish individual cannabinoids and metabolites more precisely.
The emerging research showing that THCP produces hydroxylated and carboxylated metabolites may help forensic laboratories develop more specific methods.
Anyone subject to workplace, legal or sporting drug testing should not assume that a product marketed as an alternative cannabinoid will be invisible to testing.
Is THCP legal in the UK?
This is another area where simplistic product marketing can cause confusion.
The fact that a cannabinoid is naturally present in cannabis does not automatically make a concentrated product legal to possess or sell in the UK.
UK controlled-drug law covers THC and various cannabinoid-related compounds and preparations. Novel cannabinoid products can also raise questions under the Psychoactive Substances Act and other legislation depending on their composition and how they are supplied.
Because individual formulations differ, consumers should be wary of retailers making sweeping claims that THCP products are unquestionably legal simply because THCP occurs naturally in cannabis.
Legal status depends on the actual substance, formulation and applicable legislation, not just the marketing name on the packet.
Is THCP safe?
There is not enough human evidence to describe THCP as proven safe.
That does not mean researchers have established that THCP is uniquely dangerous either.
It means the evidence base is small.
We have laboratory receptor research, animal experiments, emerging metabolism research and a limited number of human clinical reports. What we do not have is the large body of controlled trials and observational data that would allow confident conclusions about dose, adverse-event frequency, long-term effects or interactions with medicines and other drugs.
Anyone with significant cardiovascular or psychiatric conditions, anyone taking medication, and anyone who is pregnant or breastfeeding should be particularly cautious about experimenting with poorly studied psychoactive cannabinoids and should seek appropriate professional medical advice.
Why THCP is scientifically interesting
Strip away the marketing and THCP is still fascinating.
Its discovery showed that cannabis chemistry remains more complicated than the familiar THC-versus-CBD conversation suggests.
The seven-carbon side chain provided researchers with another natural example of how small structural differences can dramatically alter cannabinoid receptor interactions.
THCP has also encouraged researchers to look more closely at minor cannabinoids that occur at concentrations too low to attract the attention historically given to THC and CBD.
A 2025 laboratory study investigating ten minor cannabinoids, including THCP, found different dose-related effects in a neuronal model. Research like this may help scientists understand the pharmacology of less common cannabinoids, but laboratory findings should not be presented as proven therapeutic benefits in people.
That’s an important distinction for Black Hash because the most interesting story about THCP isn’t that someone has found “THC but 33 times stronger”.
It’s that scientists are still finding and characterising cannabinoids in a plant humans have been studying for decades.
The bottom line on THCP
THCP is real, naturally occurring and scientifically interesting.
It also has strong affinity for cannabinoid receptors and demonstrated THC-like effects in animal research.
What we don’t yet have is enough human evidence to support many of the precise claims made about it online.
The famous “33 times stronger” claim should be retired. The original research showed approximately 33-fold greater CB1 binding affinity compared with delta-9 THC in the referenced